Health & Medicine

A neoteric’s view

Page 2 of 16

Does legislation really make a difference to the health of women? A quarter of a century ago, the USA legislated in the Women’s Health Equity Act to remove the inequalities between men and women in medical research. More recently, Health Canada recommended comparative studies in healthy male and/or female volunteers to minimize variability. Nonetheless, nothing has really […]

Two decades into our new century and the pieces of the medical puzzle still don’t fit together. Administrators, algorithm developers and funders each form a rigid static piece, promoting standardization of services, while physicians and patients desire developing more customized pieces. The prospect of any union is poor – unless the pieces can fit organically […]

Traditional wisdom about chronic diseases holds that they usually last for three months or longer and may worsen over time.  They are supposed to occur more in older adults and can usually be controlled but not cured. Conditions, which we thought worsen with age, paradoxically provide some protection. As with preventable disease, identifying risks early in […]

Almost one in four of us has two or more health conditions. With each additional disease, morbidity, mortality and poly pharmacy increases. Some think multiple health problems can be cured by minimizing the uncoordinated care that comes with trying to deal with a number of health problems sequentially and that the focus should be on the […]

What goes in must come out – in some form or another. Our bodies are relatively efficient processing systems, so when we have extracted what we require from pharmaceutical agents, the rest is excreted in urine and faeces and finally makes its way to our wastewater.  Seventy-two percent of these pharmaceuticals end up in our […]

Everyone knows that the economic value of medical research is difficult to measure but the returns for our communities are great. A global assessment of the return on investment in medical research would encourage even the most bearish of investors. In the UK, for example, a government spend of £1 can yield 25 pence of benefits […]